BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33356630)

  • 1. Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma.
    Kim Y; Lee HA; Lee JS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Um SH; Seo YS; Kim SU
    Cancer Invest; 2021 Mar; 39(3):274-283. PubMed ID: 33356630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
    J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Y90 Radioembolization for Hepatocellular Carcinoma in Patients Previously Treated with Transarterial Embolization.
    Zhao K; Son S; Karimi A; Marinelli B; Erinjeri JP; Alexander ES; Sotirchos VS; Harding JJ; Soares KC; Ziv E; Covey A; Sofocleous CT; Yarmohammadi H
    Curr Oncol; 2024 May; 31(5):2650-2661. PubMed ID: 38785481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study.
    Abdallah MA; Wongjarupong N; Hassan MA; Taha W; Abdalla A; Bampoh S; Onyirioha K; Nelson M; Glubranson LA; Wiseman GA; Fleming CJ; Andrews JC; Mahipal A; Roberts LR
    Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):619-629. PubMed ID: 32490691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma.
    Labgaa I; Tabrizian P; Titano J; Kim E; Thung SN; Florman S; Schwartz M; Melloul E
    HPB (Oxford); 2019 Nov; 21(11):1497-1504. PubMed ID: 31005494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
    Kallini JR; Gabr A; Salem R; Lewandowski RJ
    Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Early Response to Treatment of Hepatocellular Carcinoma with Yttrium-90 Radioembolization Using Quantitative Computed Tomography Analysis.
    Kim S; Kim DY; An C; Han K; Won JY; Kim GM; Kim MJ; Choi JY
    Korean J Radiol; 2019 Mar; 20(3):449-458. PubMed ID: 30799576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic activity assessment by
    Kim DY; Lee HW; Kang W; Kim GM; Won JY; Yun M
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1679-1684. PubMed ID: 33226706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival comparison of hepatocellular carcinoma patients treated with radioembolization versus nonoperative/interventional treatment.
    Thayer D; Noda C; Charalel R; Mills A; Chang R; Tao Y; Akinwande O
    J Comp Eff Res; 2018 Apr; 7(4):343-356. PubMed ID: 29553286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.
    Lobo L; Yakoub D; Picado O; Ripat C; Pendola F; Sharma R; ElTawil R; Kwon D; Venkat S; Portelance L; Yechieli R
    Cardiovasc Intervent Radiol; 2016 Nov; 39(11):1580-1588. PubMed ID: 27586657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Radioembolization Treatment as a Bridge to Surgical Resection in Pediatric Hepatocellular Carcinoma.
    Whitlock RS; Loo C; Patel K; Bista R; Goss JA; Heczey A; Khan O; Lopez-Terrada D; Masand P; Nguyen H; Mahvash A; Vasudevan SA; Kukreja K
    J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1181-e1185. PubMed ID: 33769387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE).
    Quartuccio N; Ialuna S; Scalisi D; D'Amato F; Barcellona MR; Bavetta MG; Fusco G; Bronte E; Musso E; Bronte F; Picciotto V; Carroccio A; Verderame F; Malizia G; Cistaro A; La Gattuta F; Moreci AM
    Curr Oncol; 2024 Mar; 31(3):1504-1514. PubMed ID: 38534947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis.
    Bitterman DS; Sanford NN; Niemierko A; Mahal BA; Qadan M; Ganguli S; Blaszkowsky LS; Zhu AX; Hong TS; Devlin PM; Goyal L; Wo JY
    Am J Clin Oncol; 2019 Jul; 42(7):564-572. PubMed ID: 31166209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
    Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
    World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation.
    Zori AG; Ismael MN; Limaye AR; Firpi R; Morelli G; Soldevila-Pico C; Suman A; Vogel JD; Lazarowicz M; Geller BS; Toskich B; Gonzalo DH; Johnson MW; Cabrera R
    Am J Clin Oncol; 2020 May; 43(5):325-333. PubMed ID: 32079854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.